$8.73
0.516.20%
At Close: -
$8.73
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Solid Biosciences
SLDBNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Solid Biosciences (NASDAQ:SLDB) Stock, Analyst Ratings, Price Targets, Forecasts
Solid Biosciences Inc has a consensus price target of $15.25 based on the ratings of 12 analysts. The high is $40 issued by William Blair on March 28, 2024. The low is $5 issued by Cantor Fitzgerald on September 22, 2023. The 3 most-recent analyst ratings were released by JP Morgan, Leerink Partners, and Piper Sandler on July 15, 2024, June 24, 2024, and June 21, 2024, respectively. With an average price target of $15.67 between JP Morgan, Leerink Partners, and Piper Sandler, there's an implied 79.46% upside for Solid Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Leerink Partners
Piper Sandler
HC Wainwright & Co.
Barclays
1calculated from analyst ratings
Analyst Ratings for Solid Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/15/2024 | Buy Now | 71.82% | JP Morgan | Anupam Rama | $10 → $15 | Upgrade | Neutral → Overweight | Get Alert |
| 06/24/2024 | Buy Now | 37.46% | Leerink Partners | Joseph Schwartz | $12 → $12 | Upgrade | Market Perform → Outperform | Get Alert |
| 06/21/2024 | Buy Now | 129.1% | Piper Sandler | Biren Amin | $20 → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 05/31/2024 | Buy Now | 14.55% | JP Morgan | Anupam Rama | $12 → $10 | Maintains | Neutral | Get Alert |
| 05/20/2024 | Buy Now | 83.28% | HC Wainwright & Co. | Arthur He | → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 106.19% | Barclays | Gena Wang | $21 → $18 | Maintains | Overweight | Get Alert |
| 03/28/2024 | Buy Now | 358.19% | William Blair | Tim Lugo | → $40 | Initiates | → Outperform | Get Alert |
| 03/18/2024 | Buy Now | 140.55% | Barclays | Gena Wang | $8 → $21 | Maintains | Overweight | Get Alert |
| 03/15/2024 | Buy Now | 83.28% | Citigroup | David Hoang | → $16 | Initiates | → Buy | Get Alert |
| 03/14/2024 | Buy Now | 83.28% | HC Wainwright & Co. | Arthur He | → $16 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | 129.1% | Piper Sandler | Allison Bratzel | $8 → $20 | Upgrade | Neutral → Overweight | Get Alert |
| 03/11/2024 | Buy Now | 83.28% | HC Wainwright & Co. | Arthur He | $9 → $16 | Maintains | Buy | Get Alert |
| 12/08/2023 | Buy Now | 3.09% | HC Wainwright & Co. | Swayampakula Ramakanth | → $9 | Initiates | → Buy | Get Alert |
| 09/22/2023 | Buy Now | -42.73% | Cantor Fitzgerald | Charles Duncan | → $5 | Initiates | → Overweight | Get Alert |
| 11/11/2022 | Buy Now | -8.36% | Barclays | Gena Wang | $2 → $8 | Maintains | Overweight | Get Alert |
| 11/11/2022 | Buy Now | -8.36% | Piper Sandler | Allison Bratzel | $15 → $8 | Maintains | Neutral | Get Alert |
| 11/10/2022 | Buy Now | -31.27% | SVB Leerink | Joseph Schwartz | $1 → $6 | Maintains | Market Perform | Get Alert |
| 10/17/2022 | Buy Now | -88.55% | SVB Leerink | Joseph Schwartz | $180 → $15 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/30/2022 | Buy Now | — | JP Morgan | Anupam Rama | — | Upgrade | Underweight → Neutral | Get Alert |
| 08/12/2022 | Buy Now | -31.27% | Chardan Capital | Geulah Livshits | $105 → $90 | Maintains | Buy | Get Alert |
| 05/19/2022 | Buy Now | -77.09% | Piper Sandler | Allison Bratzel | $75 → $30 | Maintains | Neutral | Get Alert |
| 04/28/2022 | Buy Now | -42.73% | Piper Sandler | Allison Bratzel | $90 → $75 | Maintains | Neutral | Get Alert |
| 04/28/2022 | Buy Now | 71.82% | SVB Leerink | Joseph Schwartz | $180 → $225 | Maintains | Outperform | Get Alert |
| 04/28/2022 | Buy Now | -19.82% | Chardan Capital | Geulah Livshits | $255 → $105 | Maintains | Buy | Get Alert |
| 09/24/2021 | Buy Now | 94.73% | Chardan Capital | Geulah Livshits | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Solid Biosciences (SLDB) stock?
The latest price target for Solid Biosciences (NASDAQ:SLDB) was reported by JP Morgan on July 15, 2024. The analyst firm set a price target for $15.00 expecting SLDB to rise to within 12 months (a possible 71.82% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Solid Biosciences (SLDB)?
The latest analyst rating for Solid Biosciences (NASDAQ:SLDB) was provided by JP Morgan, and Solid Biosciences upgraded their overweight rating.
When was the last upgrade for Solid Biosciences (SLDB)?
The last upgrade for Solid Biosciences Inc happened on July 15, 2024 when JP Morgan raised their price target to $15. JP Morgan previously had a neutral for Solid Biosciences Inc.
When was the last downgrade for Solid Biosciences (SLDB)?
The last downgrade for Solid Biosciences Inc happened on October 17, 2022 when SVB Leerink changed their price target from $12 to $1 for Solid Biosciences Inc.
When is the next analyst rating going to be posted or updated for Solid Biosciences (SLDB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Solid Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Solid Biosciences was filed on July 15, 2024 so you should expect the next rating to be made available sometime around July 15, 2025.
Is the Analyst Rating Solid Biosciences (SLDB) correct?
While ratings are subjective and will change, the latest Solid Biosciences (SLDB) rating was a upgraded with a price target of $10.00 to $15.00. The current price Solid Biosciences (SLDB) is trading at is $8.73, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.